Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the <scp>FIGHT</scp> trial-Reference-Cited by-同舟云学术

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial

Published:2022-09-21 Issue:1 Volume:25 Page:189-197
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Neves João Sérgio¹²^ORCID,Vasques‐Nóvoa Francisco¹³,Borges‐Canha Marta¹²^ORCID,Leite Ana Rita¹,Sharma Abhinav⁴,Carvalho Davide²⁵^ORCID,Packer Milton⁶⁷^ORCID,Zannad Faiez⁸,Leite‐Moreira Adelino¹⁹,Ferreira João Pedro¹⁸^ORCID

Affiliation:

1. Cardiovascular R&D Centre—UnIC@RISE, Department of Surgery and Physiology Faculty of Medicine of the University of Porto Porto Portugal

2. Department of Endocrinology, Diabetes and Metabolism Centro Hospitalar Universitário de São João Porto Portugal

3. Department of Internal Medicine Centro Hospitalar Universitário de São João Porto Portugal

4. Division of Cardiology, DREAM‐CV Lab McGill University Health Centre Montreal Canada

5. Instituto de Investigação e Inovação em Saúde, Universidade do Porto Porto Portugal

6. Baylor Heart and Vascular Institute Baylor University Medical Center Dallas Texas USA

7. Imperial College London UK

8. Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14‐33, and Inserm U1116, CHRU Nancy, F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Nancy France

9. Department of Cardiothoracic Surgery Centro Hospitalar Universitário São João Porto Portugal

Funder

Fundação para a Ciência e a Tecnologia

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14862

Reference39 articles.

1. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

3. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes‐2022;Draznin B;Diabetes Care,2022

4. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

5. The Cardiovascular Biology of Glucagon-like Peptide-1

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction;Heart Failure Reviews;2024-09-13

2. Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?;Journal of the American College of Cardiology;2024-09

3. Obesity and Weight Loss Strategies for Patients With Heart Failure;JACC: Heart Failure;2024-09

4. Managing Obesity in Heart Failure: Latest Evidence and Knowledge Gaps;Current Treatment Options in Cardiovascular Medicine;2024-08-28

5. Contractile Effects of Semaglutide in the Human Atrium;Pharmaceutics;2024-08-28